Research ExplorerPublicationsThe relationship between homoarginine and liver biomarkers: ...

The relationship between homoarginine and liver biomarkers: a combination of epidemiological and clinical studies

Standard

The relationship between homoarginine and liver biomarkers: a combination of epidemiological and clinical studies. / Aghdassi, Ali; Schwedhelm, Edzard; Atzler, Dorothee; Nauck, Matthias; Kühn, Jens-Peter; Kromrey, Marie-Luise; Völzke, Henry; Felix, Stephan B; Dörr, Marcus; Ittermann, Till; Bahls, Martin.

In: SCI REP-UK, Vol. 13, No. 1, 30.03.2023, p. 5230.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Aghdassi, A, Schwedhelm, E, Atzler, D, Nauck, M, Kühn, J-P, Kromrey, M-L, Völzke, H, Felix, SB, Dörr, M, Ittermann, T & Bahls, M 2023, 'The relationship between homoarginine and liver biomarkers: a combination of epidemiological and clinical studies', SCI REP-UK, vol. 13, no. 1, pp. 5230. https://doi.org/10.1038/s41598-023-32363-4

APA

Aghdassi, A., Schwedhelm, E., Atzler, D., Nauck, M., Kühn, J-P., Kromrey, M-L., Völzke, H., Felix, S. B., Dörr, M., Ittermann, T., & Bahls, M. (2023). The relationship between homoarginine and liver biomarkers: a combination of epidemiological and clinical studies. SCI REP-UK, 13(1), 5230. https://doi.org/10.1038/s41598-023-32363-4

Vancouver

Aghdassi A, Schwedhelm E, Atzler D, Nauck M, Kühn J-P, Kromrey M-L et al. The relationship between homoarginine and liver biomarkers: a combination of epidemiological and clinical studies. SCI REP-UK. 2023 Mar 30;13(1):5230. https://doi.org/10.1038/s41598-023-32363-4

Bibtex

@article{283e90b113d340929602911552c7080b,
title = "The relationship between homoarginine and liver biomarkers: a combination of epidemiological and clinical studies",
abstract = "Homoarginine (hArg) is a non-essential cationic amino acid which inhibits hepatic alkaline phosphatases to exert inhibitory effects on bile secretion by targeting intrahepatic biliary epithelium. We analyzed (1) the relationship between hArg and liver biomarkers in two large population-based studies and (2) the impact of hArg supplementation on liver biomarkers. We assessed the relationship between alanine transaminase (ALT), aspartate aminotransferase (AST), γ-glutamyltransferase (GGT), alkaline phosphatases (AP), albumin, total bilirubin, cholinesterase, Quick's value, liver fat, and Model for End-stage Liver Disease (MELD) and hArg in appropriately adjusted linear regression models. We analyzed the effect of L-hArg supplemention (125 mg L-hArg daily for 4 weeks) on these liver biomarkers. We included 7638 individuals (men: 3705; premenopausal women: 1866, postmenopausal women: 2067). We found positive associations for hArg and ALT (β 0.38 µkatal/L 95% confidence interval (CI): 0.29; 0.48), AST (β 0.29 µkatal/L 95% CI 0.17; 0.41), GGT (β 0.033 µkatal/L 95% CI 0.014; 0.053), Fib-4 score (β 0.08 95% CI 0.03; 0.13), liver fat content (β 0.016% 95% CI 0.006; 0.026), albumin (β 0.030 g/L 95% CI 0.019; 0.040), and cholinesterase (β 0.003 µkatal/L 95% CI 0.002; 0.004) in males. In premenopausal women hArg was positively related with liver fat content (β 0.047% 95%CI 0.013; 0.080) and inversely with albumin (β - 0.057 g/L 95% CI - 0.073; - 0.041). In postmenopausal women hARG was positively associated with AST (β 0.26 µkatal/L 95% CI 0.11; 0.42). hArg supplementation did not affect liver biomarkers. We summarize that hArg may be a marker of liver dysfunction and should be explored further.",
keywords = "Male, Humans, Female, Homoarginine/pharmacology, End Stage Liver Disease, Severity of Illness Index, Liver, Biomarkers, Alanine Transaminase, gamma-Glutamyltransferase, Alkaline Phosphatase, Albumins",
author = "Ali Aghdassi and Edzard Schwedhelm and Dorothee Atzler and Matthias Nauck and Jens-Peter K{\"u}hn and Marie-Luise Kromrey and Henry V{\"o}lzke and Felix, {Stephan B} and Marcus D{\"o}rr and Till Ittermann and Martin Bahls",
note = "{\textcopyright} 2023. The Author(s).",
year = "2023",
month = mar,
day = "30",
doi = "10.1038/s41598-023-32363-4",
language = "English",
volume = "13",
pages = "5230",
journal = "SCI REP-UK",
issn = "2045-2322",
publisher = "NATURE PUBLISHING GROUP",
number = "1",

}

RIS

TY - JOUR

T1 - The relationship between homoarginine and liver biomarkers: a combination of epidemiological and clinical studies

AU - Aghdassi, Ali

AU - Schwedhelm, Edzard

AU - Atzler, Dorothee

AU - Nauck, Matthias

AU - Kühn, Jens-Peter

AU - Kromrey, Marie-Luise

AU - Völzke, Henry

AU - Felix, Stephan B

AU - Dörr, Marcus

AU - Ittermann, Till

AU - Bahls, Martin

N1 - © 2023. The Author(s).

PY - 2023/3/30

Y1 - 2023/3/30

N2 - Homoarginine (hArg) is a non-essential cationic amino acid which inhibits hepatic alkaline phosphatases to exert inhibitory effects on bile secretion by targeting intrahepatic biliary epithelium. We analyzed (1) the relationship between hArg and liver biomarkers in two large population-based studies and (2) the impact of hArg supplementation on liver biomarkers. We assessed the relationship between alanine transaminase (ALT), aspartate aminotransferase (AST), γ-glutamyltransferase (GGT), alkaline phosphatases (AP), albumin, total bilirubin, cholinesterase, Quick's value, liver fat, and Model for End-stage Liver Disease (MELD) and hArg in appropriately adjusted linear regression models. We analyzed the effect of L-hArg supplemention (125 mg L-hArg daily for 4 weeks) on these liver biomarkers. We included 7638 individuals (men: 3705; premenopausal women: 1866, postmenopausal women: 2067). We found positive associations for hArg and ALT (β 0.38 µkatal/L 95% confidence interval (CI): 0.29; 0.48), AST (β 0.29 µkatal/L 95% CI 0.17; 0.41), GGT (β 0.033 µkatal/L 95% CI 0.014; 0.053), Fib-4 score (β 0.08 95% CI 0.03; 0.13), liver fat content (β 0.016% 95% CI 0.006; 0.026), albumin (β 0.030 g/L 95% CI 0.019; 0.040), and cholinesterase (β 0.003 µkatal/L 95% CI 0.002; 0.004) in males. In premenopausal women hArg was positively related with liver fat content (β 0.047% 95%CI 0.013; 0.080) and inversely with albumin (β - 0.057 g/L 95% CI - 0.073; - 0.041). In postmenopausal women hARG was positively associated with AST (β 0.26 µkatal/L 95% CI 0.11; 0.42). hArg supplementation did not affect liver biomarkers. We summarize that hArg may be a marker of liver dysfunction and should be explored further.

AB - Homoarginine (hArg) is a non-essential cationic amino acid which inhibits hepatic alkaline phosphatases to exert inhibitory effects on bile secretion by targeting intrahepatic biliary epithelium. We analyzed (1) the relationship between hArg and liver biomarkers in two large population-based studies and (2) the impact of hArg supplementation on liver biomarkers. We assessed the relationship between alanine transaminase (ALT), aspartate aminotransferase (AST), γ-glutamyltransferase (GGT), alkaline phosphatases (AP), albumin, total bilirubin, cholinesterase, Quick's value, liver fat, and Model for End-stage Liver Disease (MELD) and hArg in appropriately adjusted linear regression models. We analyzed the effect of L-hArg supplemention (125 mg L-hArg daily for 4 weeks) on these liver biomarkers. We included 7638 individuals (men: 3705; premenopausal women: 1866, postmenopausal women: 2067). We found positive associations for hArg and ALT (β 0.38 µkatal/L 95% confidence interval (CI): 0.29; 0.48), AST (β 0.29 µkatal/L 95% CI 0.17; 0.41), GGT (β 0.033 µkatal/L 95% CI 0.014; 0.053), Fib-4 score (β 0.08 95% CI 0.03; 0.13), liver fat content (β 0.016% 95% CI 0.006; 0.026), albumin (β 0.030 g/L 95% CI 0.019; 0.040), and cholinesterase (β 0.003 µkatal/L 95% CI 0.002; 0.004) in males. In premenopausal women hArg was positively related with liver fat content (β 0.047% 95%CI 0.013; 0.080) and inversely with albumin (β - 0.057 g/L 95% CI - 0.073; - 0.041). In postmenopausal women hARG was positively associated with AST (β 0.26 µkatal/L 95% CI 0.11; 0.42). hArg supplementation did not affect liver biomarkers. We summarize that hArg may be a marker of liver dysfunction and should be explored further.

KW - Male

KW - Humans

KW - Female

KW - Homoarginine/pharmacology

KW - End Stage Liver Disease

KW - Severity of Illness Index

KW - Liver

KW - Biomarkers

KW - Alanine Transaminase

KW - gamma-Glutamyltransferase

KW - Alkaline Phosphatase

KW - Albumins

U2 - 10.1038/s41598-023-32363-4

DO - 10.1038/s41598-023-32363-4

M3 - SCORING: Journal article

C2 - 36997574

VL - 13

SP - 5230

JO - SCI REP-UK

JF - SCI REP-UK

SN - 2045-2322

IS - 1

ER -